The Spinal Muscular Atrophy market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Spinal Muscular Atrophy: An Overview
According to the National Institute of Health (NIH), Spinal muscular atrophy is a genetic disorder characterized by weakness and wasting (atrophy) in muscles used for movement (skeletal muscles). It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement. The weakness tends to be more severe in the muscles that are close to the center of the body (proximal) compared to muscles away from the body’s center (distal). The muscle weakness usually worsens with age.
SMA is a motor neuron disease caused by Bi-allelic mutation of survival motor neuron gene 1 (SMN1). There are two identical genes SMN1 (telomeric copy) and SMN2 (centromeric copy) present at human chromosome 5q13. These genes are responsible to synthesize survival motor neuron protein which is necessary for the normal function of motor neurons that control our muscles. The insufficient production of SMN proteins leads to debilitating and often fatal muscle weakness.
Spinal Muscular Atrophy Market Key Facts
The total prevalent population of Spinal Muscular Atrophy (SMA) in the seven major markets was 19,343 in 2017.
As per the estimates, among the EU5 countries, Germany had the highest prevalent population of Spinal Muscular Atrophy with 1,643 cases in 2017 followed by the UK and France. On the other hand, Spain had the lowest prevalence with 468 cases in 2017.
As per DelveInsight analysis, the diagnosed prevalent cases of Spinal Muscular Atrophy in the United States were found to be 11,733 in 2017.
As per the study conducted by B. Melissa et al., (2017), Spinal muscular atrophy (SMA) is the most common genetic disease resulting in death in infancy, affecting approximately 1 in 6,000 to 1 in 10,000 births. Therapies that improve neuromuscular function as well as maintain the lifelong general health of people living with SMA are therefore a major priority and an unmet clinical need.
Spinal Muscular Atrophy Market
Approaches for management of Spinal Muscular Atrophy lays focus on Nutrition, Respiratory Care Assessment, Respiratory Muscle Weakness, Orthopedic Care, Rehabilitation, along with few medications. Extensive research and development activities of pharmaceutical companies, along with rising prevalence are expected to fuel the growth of the market in the coming years.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Spinal Muscular Atrophy market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Spinal Muscular Atrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Request for Sample @ Spinal Muscular Atrophy Therapeutics Market Assessment
Spinal Muscular Atrophy Epidemiology
The epidemiology section covers insights about the historical and current Spinal Muscular Atrophy patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Spinal Muscular Atrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Spinal Muscular Atrophy market or expected to get launched in the market during the study period. The analysis covers Spinal Muscular Atrophy market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Spinal Muscular Atrophy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
The Spinal Muscular Atrophy pipeline possesses multiple potential drugs in late and mid-stage developments that are expected to be launched in the near future.
Some of the key companies developing therapies for the treatment of Spinal Muscular Atrophy include:
And many others.
Spinal Muscular Atrophy Therapies covered in the report includes:
Amifampridine Phosphate (Firdapse)
And few others.
Request for sample copy at: https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight
Table of Content
1. Key Insights
2. Executive Summary
3. Spinal Muscular Atrophy Competitive Intelligence Analysis
4. Spinal Muscular Atrophy Market Overview at a Glance
5. Spinal Muscular Atrophy Disease Background and Overview
6. Spinal Muscular Atrophy Patient Journey
7. Spinal Muscular Atrophy Epidemiology and Patient Population
8. Spinal Muscular Atrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Spinal Muscular Atrophy Unmet Needs
10. Key Endpoints of Spinal Muscular Atrophy Treatment
11. Spinal Muscular Atrophy Marketed Products
12. Spinal Muscular Atrophy Emerging Therapies
13. Spinal Muscular Atrophy Seven Major Market Analysis
14. Attribute Analysis
15. Spinal Muscular Atrophy Market Outlook (7 major markets)
16. Spinal Muscular Atrophy Access and Reimbursement Overview
17. KOL Views on the Spinal Muscular Atrophy Market.
18. Spinal Muscular Atrophy Market Drivers
19. Spinal Muscular Atrophy Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight
Latest Reports By DelveInsight
Spinal Muscular Atrophy (SMA) Pipeline Insights
Spinal Muscular Atrophy (SMA) Pipeline Insight, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Spinal Muscular Atrophy (SMA) market.
Global Kinase Inhibitor in Autoimmune Diseases Market
DelveInsight’s “Global Kinase Inhibitor in Autoimmune Diseases Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Global Kinase Inhibitor in Autoimmune Diseases market size, shares, and trends analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States